Scientific References Fenbendazole

Study 1

The Discovery

Dogra N, et al. (2018). Fenbendazole acts as a moderate microtubule destabilizing agent and causes cancer cell death by modulating multiple cellular pathways. Scientific Reports, 8:11926.

Study 2

Proof in Action

Duan Q, et al. (2013). The anthelmintic drug fenbendazole exhibits anticancer properties through multiple mechanisms. Cancer Letters, 335(1).

Lei X, et al. (2025). Fenbendazole inhibits tumor growth and induces apoptosis in cervical cancer models. Molecules, 30(11):2377.

Study 3

Breaking Resistance

Park S, et al. (2022). Fenbendazole sensitizes 5-fluorouracil–resistant colorectal cancer cells to treatment. International Journal of Molecular Sciences, 23(16):9437363.

Chang J, et al. (2023). Fenbendazole nanoparticles enhance anticancer effects in ovarian cancer models. Journal of Gynecologic Oncology, 34:e58.

Study 4

Human Breakthroughs

Nguyen T, et al. (2024). Case series: Oral fenbendazole in oncology patients — pharmacokinetics and tolerability. Anticancer Research, 44(9):3725–3732.

Makis W, et al. (2025). Fenbendazole as an anticancer agent? Case series in advanced cancers. Anticancer Research (PubMed ID: 40605964).

Study 5

Advanced Mechanistic Insights

Wang Y, et al. (2024). Transcriptome analysis reveals anticancer mechanisms of fenbendazole in ovarian cancer models. BMC Cancer, 24:13361.